JMP Securities Initiates Coverage On Rhythm Pharmaceuticals with Market Outperform Rating, Announces Price Target of $64
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has initiated coverage on Rhythm Pharmaceuticals with a Market Outperform rating and set a price target of $64.
September 17, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has initiated coverage on Rhythm Pharmaceuticals with a Market Outperform rating and a price target of $64, indicating a positive outlook.
The initiation of coverage with a Market Outperform rating and a specific price target of $64 by JMP Securities suggests a positive sentiment towards Rhythm Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100